Rafael Holdings, Inc. (RFL) - 10-Q Summary
Business Context and Reporting Period
This filing covers the quarterly period ended April 30, 2026 (Fiscal Q3 2026). Rafael Holdings, Inc. is a biotechnology company focused on developing pharmaceuticals and holding interests in clinical-stage companies. The primary strategic focus is the development of Trappsol® Cyclo™ for Niemann-Pick Disease Type C1 (NPC1), following the March 2025 merger with Cyclo Therapeutics. The company operates through three segments: Healthcare, Infusion Technology, and Real Estate.
Key Financial Metrics (Nine Months Ended April 30, 2026)
| Metric | Amount (in thousands) |
|---|---|
| Total Revenue | $630 |
| Net Loss (Consolidated) | $(19,022) |
| Net Loss Attributable to Rafael Holdings | $(20,459) |
| Loss Per Share (Basic & Diluted) | $(0.40) |
| Cash and Cash Equivalents (Ending) | $30,497 |
| Net Cash Used in Operating Activities | $(21,613) |
| Total Assets | $91,990 |
| Total Liabilities | $11,187 |
| Working Capital | $23,838 |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased to $630,000 for the nine months ended April 30, 2026, compared to $567,000 in the prior year period. This was driven by product revenue ($368,000 vs. $243,000) and rental revenue ($262,000 vs. $231,000). However, Infusion Technology revenue dropped to zero following the sale of assets in March 2025.
- Operating Loss: Loss from operations widened to $(23.7) million from $(16.4) million. This increase is primarily due to higher Research and Development (R&D) expenses of $16.9 million (vs. $5.3 million), driven by the consolidation of Cyclo Therapeutics and clinical trial activities.
- Non-Operating Gains: The company recognized a significant gain on settlement of accounts payable and convertible notes payable of $3.96 million, resulting from debt settlements with Cornerstone creditors and note holders. This gain significantly reduced the consolidated net loss.
- Cash Position: Cash and cash equivalents decreased by $22.3 million to $30.5 million, primarily due to operating cash outflows of $21.6 million and investing outflows related to new investments.
Guidance, Outlook, and Risks
- Clinical Milestones: In June 2026 (subsequent event), the company announced the completion of the final 96-week visit in its pivotal Phase 3 TransportNPC™ study for Trappsol® Cyclo™. Topline results are expected in the second half of calendar 2026.
- Regulatory Filing: The company completed a pre-New Drug Application (NDA) meeting with the FDA and expects to submit an NDA for Trappsol® Cyclo™ in the second half of 2026.
- Liquidity: Management expects current cash balances to be sufficient to meet obligations for at least the next 12 months.
- Internal Controls: A material weakness in internal control over financial reporting was identified at the acquired Cyclo subsidiary regarding accruals and clinical trial expenses. A remediation plan is underway to integrate Cyclo's processes into the parent company's controls.
- Risks: Key risks include the success of the Phase 3 clinical trial, the ability to secure additional funding if needed, and the integration of acquired entities.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $30.5 million cash balance against the projected burn rate for the Phase 3 trial completion and NDA submission.
- Debt Settlement Details: Review the specific terms of the $3.96 million gain on debt settlement to understand the remaining liability profile for Cornerstone.
- Internal Control Remediation: Monitor the progress of the remediation plan for the material weakness identified at Cyclo Therapeutics.
- Clinical Trial Data: Await the topline results of the Phase 3 TransportNPC™ study expected in late 2026, which is the primary value driver.
- Segment Performance: Note the cessation of Infusion Technology revenue and the shift in focus entirely to Healthcare (Cyclo) and Real Estate segments.